Using IPA, we found several pathways including estrogen-mediated S-phase entry, basal cell carcinoma signaling, osteoarthritis pathway, and P53 signaling that were either inhibited or had a trend towards inhibition (based on Z score) in doxorubicin-treated MCF7/LMTK3 cells compared to doxorubicin-treated MCF7 cells. This evidence concerns the gene TP53 and osteoarthritis.